Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
NovoCure Ltd (NVCR)
NASDAQ:NVCR
Holding NVCR?
Track your performance easily
NVCR Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$10.87 - $24.74
Previous Close$18.02
Volume542.04K
Average Volume (3M)1.39M
Market Cap
$1.95B
Enterprise Value$1.67B
Total Cash (Recent Filing)$951.19M
Total Debt (Recent Filing)$675.20M
Price to Earnings (P/E)―
Beta1.58
Next Earnings
Oct 24, 2024EPS Estimate
-$0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.57
Shares Outstanding108,217,490
10 Day Avg. Volume1,000,148
30 Day Avg. Volume1,385,840
Standard Deviation0.21
R-Squared0.03
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)5.39
Price to Sales (P/S)3.53
Price to Cash Flow (P/CF)-292.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.04
Enterprise Value/Gross Profit4.39
Enterprise Value/Ebitda-12.72
Forecast
1Y Price Target
$26.00Price Target Upside47.64% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
NovoCure News
PremiumCompany Announcements
NovoCure Announces Major Leadership Restructuring and New Roles
PremiumCompany Announcements
NovoCure Shareholders Elect Directors and Endorse Key ProposalsBulls Say, Bears Say
Bulls Say
Financial PerformanceNVCR reported total 2Q24 revenues of $150.4M, above consensus estimates of $135.8M and an 8.6% increase over reported 1Q24 revenues.
Patient GrowthThe company noted that there are 3,963 active patients on therapy as of 2Q24, which is a record high.
Product LaunchNVCR emphasized the contributions of the successful ongoing launch of TTFields in France, alongside an increase in US approval rates to the strong revenues in 2Q24.
Bears Say
Clinical StudyOverall survival did not show a significant difference between the study and control arms.
LeadershipThe company has begun an external search for a new CFO.
Sales GrowthSales in the US are unlikely to grow much going forward as the company noted it has reached approval on almost all patients now.
---
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
NVCR FAQ
What was NovoCure Ltd’s price range in the past 12 months?
NovoCure Ltd lowest stock price was $10.87 and its highest was $24.73 in the past 12 months.
What is NovoCure Ltd’s market cap?
Currently, no data Available
When is NovoCure Ltd’s upcoming earnings report date?
NovoCure Ltd’s upcoming earnings report date is Oct 24, 2024 which is in 35 days.
How were NovoCure Ltd’s earnings last quarter?
NovoCure Ltd released its earnings results on Jul 25, 2024. The company reported -$0.31 earnings per share for the quarter, beating the consensus estimate of -$0.403 by $0.093.
Is NovoCure Ltd overvalued?
According to Wall Street analysts NovoCure Ltd’s price is currently Undervalued.
Does NovoCure Ltd pay dividends?
NovoCure Ltd does not currently pay dividends.
What is NovoCure Ltd’s EPS estimate?
NovoCure Ltd’s EPS estimate is -$0.33.
How many shares outstanding does NovoCure Ltd have?
NovoCure Ltd has 108,217,490 shares outstanding.
What happened to NovoCure Ltd’s price movement after its last earnings report?
NovoCure Ltd reported an EPS of -$0.31 in its last earnings report, beating expectations of -$0.403. Following the earnings report the stock price went down -0.745%.
Which hedge fund is a major shareholder of NovoCure Ltd?
Among the largest hedge funds holding NovoCure Ltd’s share is Coatue Management, LLC. It holds NovoCure Ltd’s shares valued at 10M.
---
NovoCure Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$26.00 (47.64% Upside)
$26.00 (47.64% Upside)
Blogger Sentiment
Bullish
NVCR Sentiment 66%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 34.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-6.63%
12-Months-Change
Fundamentals
Return on Equity
-43.40%
Trailing 12-Months
Asset Growth
4.59%
Trailing 12-Months
Company Description
NovoCure Ltd
NovoCure Ltd. develops treatment for tumors. Its platform is called the Tumor Treating Field which used electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.
---
NVCR Company Deck
---
NVCR Earnings Call
Q2 2024
0:00 / 0:00
---
NVCR Net revenue Breakdown
68.67% U.S.
11.82% Germany
8.74% Japan
6.22% Other EMEA
4.56% Greater China
---
NVCR Stock 12 Month Forecast
Average Price Target
$26.00
▲(47.64% Upside)
Technical Analysis
Best Analysts Covering NVCR
1 Year
1 Year Success Rate
12/17 ratings generated profit
1 Year Average Return
+11.81%
assigned a buy rating 17 days ago
Copying Larry Biegelsen's trades and holding each position for 1 Year would result in 70.59% of your transactions generating a profit, with an average return of +11.81% per trade.
---